Jennison Associates LLC Decreases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Jennison Associates LLC lowered its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 26.0% in the fourth quarter, Holdings Channel reports. The firm owned 303,521 shares of the company’s stock after selling 106,536 shares during the period. Jennison Associates LLC’s holdings in Krystal Biotech were worth $47,550,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Summit Trail Advisors LLC acquired a new position in shares of Krystal Biotech during the third quarter valued at approximately $1,893,000. Swiss National Bank grew its holdings in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Shaker Investments LLC OH acquired a new stake in shares of Krystal Biotech in the third quarter valued at about $532,000. Citigroup Inc. boosted its position in Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after acquiring an additional 13,874 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Krystal Biotech by 9.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after acquiring an additional 19,777 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

KRYS has been the topic of several recent research reports. Citigroup boosted their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Chardan Capital reiterated a “buy” rating and set a $212.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $206.67.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Up 1.4 %

NASDAQ:KRYS opened at $161.30 on Wednesday. Krystal Biotech, Inc. has a 52 week low of $107.50 and a 52 week high of $219.34. The company has a fifty day simple moving average of $164.94 and a two-hundred day simple moving average of $178.99. The company has a market cap of $4.64 billion, a price-to-earnings ratio of 91.13 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.67) EPS. On average, analysts expect that Krystal Biotech, Inc. will post 3.22 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).